This seems odd,... is it just me or is it poorly worded,... 10% oercent reduction in MACE for Apabetalone vs 12% reduction in placebo

• Although not reaching significance in its primary outcome measure, apabetalone treatment provided a promising trend towards reduction in MACE (10.3% in apabetalone-treated and 12.4% in placebo-treated patients, hazard ratio 0.82, 95% CI 0.65-1.04), among type 2 diabetic patients with acute coronary syndrome (ACS) and low HDL cholesterol